Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 4/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.42 |
| ▸ | MMP13 | P45452 | 2/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23531641 | 0.93 | KMT2A (0.50) | MEN1KMT2AGPR119MMP13P2RX7 | |
| SCHEMBL3319115 | 0.91 | MEN1 (0.45) | MEN1KMT2ARORCGPR119MMP13 | |
| SCHEMBL19205366 | 0.86 | MEN1 (0.46) | MEN1KMT2ARORCGPR119MMP13 | |
| SCHEMBL27228991 | 0.85 | MEN1 (0.45) | MEN1KMT2ARORCGPR119MMP13 | |
| SCHEMBL4973467 | 0.85 | MEN1 (0.48) | MEN1KMT2AGPR119MMP13P2RX7 | |
| SCHEMBL27228997 | 0.84 | MEN1 (0.45) | MEN1KMT2ARORCGPR119MMP13 | |
| SCHEMBL24424679 | 0.84 | KMT2A (0.45) | MEN1KMT2ARORCGPR119MMP13 | |
| SCHEMBL16520138 | 0.84 | KMT2A (0.50) | MEN1KMT2AGPR119MMP13P2RX7 | |
| SCHEMBL619491 | 0.83 | KMT2A (0.49) | MEN1KMT2AGPR119MMP13P2RX7 | |
| SCHEMBL26855934 | 0.82 | KMT2A (0.47) | MEN1KMT2ARORCGPR119MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158392-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2024-05-16 | — | — | US | disclosed |
| EP-4284801-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | Janssen Biotech, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| WO-2022165529-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | JANSSEN BIOTECH, INC. (US) | 2022-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158392-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | SIK2, SIK1, SGK2 | MEN1 3397/4885KMT2A 2521/4885RORC 1792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.